GLUE PEER ANALYSIS

Monte Rosa Therapeutics Inc — metric-by-metric comparison with peers and the industry median

GLUEMonte Rosa Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

GLUEIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	GLUE	MSB	TLX	CSL	RTALB	Ind. Median
P/E	—	—	—	29.44	4.89●	17.91
P/B	3.04	—	6.37	2.20	0.61●	3.51
EV/EBITDA	—	—	120.14	10.21●	74.61	14.82
P/S	36.94	31.61	3.24	2.62●	6.67	10.89

Financial Health
Metric	GLUE	MSB	TLX	CSL	RTALB	Ind. Median
Current Ratio	9.54●	—	1.43	2.57	1.21	5.90
Debt/Equity	7.5%	—	112.3%	67.4%	1.2%●	10.9%
NetDebt/EBITDA	5.08	—	13.13	2.22	0.90●	1.15

Profitability
Metric	GLUE	MSB	TLX	CSL	RTALB	Ind. Median
Net Margin	-302.7%	-115.3%	-0.9%	9.2%	136.3%●	-125.7%
ROE	-32.6%	-11.3%	-1.8%	7.7%	15.1%●	-47.5%
ROA	-23.0%	-8.6%	-0.7%	3.8%	13.1%●	-35.8%
EBITDA Margin	-287.6%	-76.6%	3.0%	32.8%●	9.0%	-105.8%

Growth + Dividend
Metric	GLUE	MSB	TLX	CSL	RTALB	Ind. Median
Rev. Growth	-73.1%	410.4%●	56.3%	4.8%	24.0%	5.1%
NI Growth	—	—	—	-39.4%	134.0%●	12.1%
Div. Yield	—	0.0%	—	2.5%●	0.0%	0.2%
Payout	—	0.0%	—	103.1%	0.0%	0.0%

Valuation
Metric	GLUE	NVAX	FTRE	SVRA	VIR	PGEN	Ind. Median
P/E	—	—	—	—	—	—	17.91
P/B	3.04	-10.99●	3.00	8.95	1.82	87.24	3.51
EV/EBITDA	—	—	—	—	—	—	14.82
P/S	36.94	2.67	0.58●	—	22.59	55.87	10.89

Financial Health
Metric	GLUE	NVAX	FTRE	SVRA	VIR	PGEN	Ind. Median
Current Ratio	9.54	2.48	0.95	13.47●	7.11	4.82	5.90
Debt/Equity	7.5%	-203.8%●	212.6%	17.1%	11.8%	485.5%	10.9%
NetDebt/EBITDA	5.08	11.76	-3.45●	1.34	0.86	-0.22	1.15

Profitability
Metric	GLUE	NVAX	FTRE	SVRA	VIR	PGEN	Ind. Median
Net Margin	-302.7%	-14.7%●	-16.5%	—	-676.0%	-647.0%	-125.7%
ROE	-32.6%●	—	-64.5%	-80.0%	-47.7%	—	-47.5%
ROA	-23.0%	-7.5%●	-15.4%	-63.0%	-37.9%	-152.9%	-35.8%
EBITDA Margin	-287.6%	-7.1%●	-10.4%	—	-669.6%	-617.8%	-105.8%

Growth + Dividend
Metric	GLUE	NVAX	FTRE	SVRA	VIR	PGEN	Ind. Median
Rev. Growth	-73.1%	-52.5%	0.9%	-100.0%	214.0%	652.1%●	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on GLUE

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.